New drug aims to unmask melanoma to the immune system
NCT ID NCT03161431
First seen Dec 29, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will receive SX-682 alone first, then both drugs together for up to two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of Miami
Miami, Florida, 33136, United States
-
Wilmot Cancer Institute - University of Rochester
Rochester, New York, 14642, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SX-682 (an oral drug that blocks cancer from hiding from the immune system) and pembrolizumab (an immunotherapy that helps immune cells attack cancer)
What this could lead to
If it works, this could point toward a new combination treatment that makes immunotherapy more effective for people with advanced melanoma.
What could go wrong
This is an early Phase 1 trial with only 77 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.